| Year |
Citation |
Score |
| 2020 |
Châtre R, Lange J, Péraudeau E, Poinot P, Lerondel S, Le Pape A, Clarhaut J, Renoux B, Papot S. In vivo synthesis of triple-loaded albumin conjugate for efficient targeted cancer chemotherapy. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 32777236 DOI: 10.1016/J.Jconrel.2020.08.008 |
0.369 |
|
| 2019 |
Lange J, Eddhif B, Tarighi M, Garandeau T, Péraudeau E, Clarhaut J, Renoux B, Papot S, Poinot P. Volatile Organic Compound (VOC)-Based Probe for Induced Volatolomics of Cancers. Angewandte Chemie (International Ed. in English). PMID 31518472 DOI: 10.1002/Anie.201906261 |
0.351 |
|
| 2018 |
Renoux B, Fangous L, Hötten C, Péraudeau E, Eddhif B, Poinot P, Clarhaut J, Papot S. A β-glucuronidase-responsive albumin-binding prodrug programmed for the double release of monomethyl auristatin E. Medchemcomm. 9: 2068-2071. PMID 30746064 DOI: 10.1039/C8Md00466H |
0.303 |
|
| 2018 |
Compain G, Oumata N, Clarhaut J, Péraudeau E, Renoux B, Galons H, Papot S. A β-glucuronidase-responsive albumin-binding prodrug for potential selective kinase inhibitor-based cancer chemotherapy. European Journal of Medicinal Chemistry. 158: 1-6. PMID 30199702 DOI: 10.1016/J.Ejmech.2018.08.100 |
0.374 |
|
| 2018 |
Boucher J, Simonneau C, Denet G, Clarhaut J, Balandre AC, Mesnil M, Cronier L, Monvoisin A. Pannexin-1 in Human Lymphatic Endothelial Cells Regulates Lymphangiogenesis. International Journal of Molecular Sciences. 19. PMID 29882918 DOI: 10.3390/Ijms19061558 |
0.372 |
|
| 2017 |
Péraudeau E, Cronier L, Monvoisin A, Poinot P, Mergault C, Guilhot F, Tranoy-Opalinski I, Renoux B, Papot S, Clarhaut J. Enhancing tumor response to targeted chemotherapy through up-regulation of folate receptor α expression induced by dexamethasone and valproic acid. Journal of Controlled Release : Official Journal of the Controlled Release Society. 269: 36-44. PMID 29129656 DOI: 10.1016/J.Jconrel.2017.11.011 |
0.465 |
|
| 2017 |
Renoux B, Raes F, Legigan T, Péraudeau E, Eddhif B, Poinot P, Tranoy-Opalinski I, Alsarraf J, Koniev O, Kolodych S, Lerondel S, Le Pape A, Clarhaut J, Papot S. Targeting the tumour microenvironment with an enzyme-responsive drug delivery system for the efficient therapy of breast and pancreatic cancers. Chemical Science. 8: 3427-3433. PMID 28507714 DOI: 10.1039/C7Sc00472A |
0.375 |
|
| 2016 |
Rubio S, Clarhaut J, Péraudeau E, Vincenzi M, Soum C, Rossi F, Guillon J, Papot S, Ronga L. Diminished oligomerization in the synthesis of new anti-angiogenic cyclic peptide using solution instead of solid-phase cyclization. Biopolymers. 106: 368-75. PMID 26832831 DOI: 10.1002/Bip.22814 |
0.344 |
|
| 2015 |
Barat R, Legigan T, Tranoy-Opalinski I, Renoux B, Péraudeau E, Clarhaut J, Poinot P, Fernandes AE, Aucagne V, Leigh DA, Papot S. A mechanically interlocked molecular system programmed for the delivery of an anticancer drug. Chemical Science. 6: 2608-2613. PMID 29308165 DOI: 10.1039/C5Sc00648A |
0.366 |
|
| 2015 |
Alsarraf J, Péraudeau E, Poinot P, Tranoy-Opalinski I, Clarhaut J, Renoux B, Papot S. A dendritic β-galactosidase-responsive folate-monomethylauristatin E conjugate. Chemical Communications (Cambridge, England). 51: 15792-5. PMID 26365722 DOI: 10.1039/C5Cc05294G |
0.377 |
|
| 2014 |
Tranoy-Opalinski I, Legigan T, Barat R, Clarhaut J, Thomas M, Renoux B, Papot S. β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: an update. European Journal of Medicinal Chemistry. 74: 302-13. PMID 24480360 DOI: 10.1016/J.Ejmech.2013.12.045 |
0.363 |
|
| 2013 |
Legigan T, Clarhaut J, Renoux B, Tranoy-Opalinski I, Monvoisin A, Jayle C, Alsarraf J, Thomas M, Papot S. Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy. European Journal of Medicinal Chemistry. 67: 75-80. PMID 23845743 DOI: 10.1016/J.Ejmech.2013.06.037 |
0.345 |
|
| 2013 |
Yefimova MG, Messaddeq N, Harnois T, Meunier AC, Clarhaut J, Noblanc A, Weickert JL, Cantereau A, Philippe M, Bourmeyster N, Benzakour O. A chimerical phagocytosis model reveals the recruitment by Sertoli cells of autophagy for the degradation of ingested illegitimate substrates. Autophagy. 9: 653-66. PMID 23439251 DOI: 10.4161/Auto.23839 |
0.309 |
|
| 2012 |
Legigan T, Clarhaut J, Renoux B, Tranoy-Opalinski I, Monvoisin A, Berjeaud JM, Guilhot F, Papot S. Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin. Journal of Medicinal Chemistry. 55: 4516-20. PMID 22515366 DOI: 10.1021/Jm300348R |
0.346 |
|
| 2012 |
Strale PO, Clarhaut J, Lamiche C, Cronier L, Mesnil M, Defamie N. Down-regulation of Connexin43 expression reveals the involvement of caveolin-1 containing lipid rafts in human U251 glioblastoma cell invasion. Molecular Carcinogenesis. 51: 845-60. PMID 21882259 DOI: 10.1002/mc.20853 |
0.321 |
|
| 2011 |
Thomas M, Clarhaut J, Strale PO, Tranoy-Opalinski I, Roche J, Papot S. A galactosidase-responsive "trojan horse" for the selective targeting of folate receptor-positive tumor cells. Chemmedchem. 6: 1006-10. PMID 21442760 DOI: 10.1002/Cmdc.201100114 |
0.571 |
|
| 2010 |
Geneau G, Lamiche C, Niger C, Strale PO, Clarhaut J, Defamie N, Debiais F, Mesnil M, Cronier L. Effect of endothelin-1 on osteoblastic differentiation is modified by the level of connexin43: comparative study on calvarial osteoblastic cells isolated from Cx43+/- and Cx43+/+ mice. Cell and Tissue Research. 340: 103-15. PMID 20195637 DOI: 10.1007/S00441-009-0924-5 |
0.328 |
|
| 2009 |
Charrier C, Clarhaut J, Gesson JP, Estiu G, Wiest O, Roche J, Bertrand P. Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression. Journal of Medicinal Chemistry. 52: 3112-5. PMID 19385600 DOI: 10.1021/Jm9002439 |
0.696 |
|
| 2009 |
Clarhaut J, Gemmill RM, Potiron VA, Ait-Si-Ali S, Imbert J, Drabkin HA, Roche J. ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells. Neoplasia (New York, N.Y.). 11: 157-66. PMID 19177200 DOI: 10.1593/Neo.81074 |
0.748 |
|
| 2008 |
Karayan-Tapon L, Wager M, Guilhot J, Levillain P, Marquant C, Clarhaut J, Potiron V, Roche J. Semaphorin, neuropilin and VEGF expression in glial tumours: SEMA3G, a prognostic marker? British Journal of Cancer. 99: 1153-60. PMID 18781179 DOI: 10.1038/Sj.Bjc.6604641 |
0.693 |
|
| 2008 |
Thomas M, Clarhaut J, Tranoy-Opalinski I, Gesson JP, Roche J, Papot S. Synthesis and biological evaluation of glucuronide prodrugs of the histone deacetylase inhibitor CI-994 for application in selective cancer chemotherapy. Bioorganic & Medicinal Chemistry. 16: 8109-16. PMID 18692397 DOI: 10.1016/J.Bmc.2008.07.048 |
0.675 |
|
| 2008 |
Roche J, Clarhaut J, Gemmill R, Ait-Si-Ali S, Imbert J, Drabkin H. ZEB-1 can repress SEMA3F semaphorin – a tumor suppressor gene in lung cancer European Journal of Cancer Supplements. 6: 89-90. DOI: 10.1016/S1359-6349(08)71521-0 |
0.313 |
|
| 2007 |
Potiron VA, Sharma G, Nasarre P, Clarhaut JA, Augustin HG, Gemmill RM, Roche J, Drabkin HA. Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells. Cancer Research. 67: 8708-15. PMID 17875711 DOI: 10.1158/0008-5472.Can-06-3612 |
0.668 |
|
| 2007 |
Loudni L, Roche J, Potiron V, Clarhaut J, Bachmann C, Gesson JP, Tranoy-Opalinski I. Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors. Bioorganic & Medicinal Chemistry Letters. 17: 4819-23. PMID 17624773 DOI: 10.1016/J.Bmcl.2007.06.067 |
0.712 |
|
| 2006 |
Clarhaut J, Roche J, Drabkin HA. Semaphorins in lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 1: 203-4. PMID 17409857 DOI: 10.1016/S1556-0864(15)31568-9 |
0.668 |
|
| Show low-probability matches. |